GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Cash Conversion Cycle

Agilent Technologies (Agilent Technologies) Cash Conversion Cycle

: 141.60 (As of Jan. 2024)
View and export this data going back to 1999. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Agilent Technologies's Days Sales Outstanding for the three months ended in Jan. 2024 was 71.16.
Agilent Technologies's Days Inventory for the three months ended in Jan. 2024 was 125.56.
Agilent Technologies's Days Payable for the three months ended in Jan. 2024 was 55.12.
Therefore, Agilent Technologies's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was 141.60.


Agilent Technologies Cash Conversion Cycle Historical Data

The historical data trend for Agilent Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.52 117.68 110.83 117.84 130.04

Agilent Technologies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.99 144.75 130.74 143.87 141.60

Competitive Comparison

For the Diagnostics & Research subindustry, Agilent Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilent Technologies Cash Conversion Cycle Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's Cash Conversion Cycle falls into.



Agilent Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Agilent Technologies's Cash Conversion Cycle for the fiscal year that ended in Oct. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=72.01+112.11-54.08
=130.04

Agilent Technologies's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=71.16+125.56-55.12
=141.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agilent Technologies  (NYSE:A) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Agilent Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilent Technologies (Agilent Technologies) Business Description

Traded in Other Exchanges
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Executives
Philip Binns officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves officer: V.P., Corporate Controller 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen officer: Sr. Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen officer: CEO and President 5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten director 5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand director C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj director C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh director C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop director 60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky director 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell officer: Senior Vice President 5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051